Marc F. Ferrante
Expertise in
2
conditions

Dr. Marc F. Ferrante

Radiology
Advanced Radiology Mri Centers Lp
1259 E Main St, 
Stamford, CT 
Expertise in
2
conditions
Advanced Radiology Mri Centers Lp
1259 E Main St, 
Stamford, CT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Marc Ferrante is a Radiologist in Stamford, Connecticut. Dr. Ferrante is highly rated in 2 conditions, according to our data. His top areas of expertise are Colonic Malakoplakia, ALK-Positive Non-Small Cell Lung Cancer, Gas Bloat Syndrome, Endoscopy, and Colonoscopy.

His clinical research consists of co-authoring 342 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiology
Licenses
Diagnostic Radiology in CT
Hospital Affiliations
St Vincent's Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

ADVANCED RADIOLOGY MRI CENTERS LP
1259 E Main St, Stamford, CT 06902
Other Locations
ADVANCED RADIOLOGY CONSULTANTS LLC
4 Corporate Dr, Suite 182, Shelton, CT 06484
ADVANCED RADIOLOGY MRI CENTERS LP
60 Danbury Rd, Suite 101, Wilton, CT 06897
BRIDGEPORT RADIOLOGICAL ASSOCIATES LLC
267 Grant St, Bridgeport, CT 06610
ADVANCED RADIOLOGY CONSULTANTS LLC
15 Corporate Dr, Trumbull, CT 06611
ADVANCED RADIOLOGY MRI CENTERS LP
297 Boston Post Rd, Orange, CT 06477
ADVANCED RADIOLOGY MRI CENTERS LP
2876 Main St, Stratford, CT 06614
ADVANCED RADIOLOGY MRI CENTERS LP
1055 Post Rd, Fairfield, CT 06824
ADVANCED RADIOLOGY MRI CENTERS LP
30 Danbury Rd, Wilton, CT 06897
BRIDGEPORT RADIOLOGICAL ASSOCIATES LLC
2800 Main St, Bridgeport, CT 06606

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
VERDICT: In actiVE Ulcerative Colitis, a RanDomIzed Controlled Trial for Determination of the Optimal Treatment Target
VERDICT: In actiVE Ulcerative Colitis, a RanDomIzed Controlled Trial for Determination of the Optimal Treatment Target
Enrollment Status: Active_not_recruiting
Publish Date: September 11, 2025
Intervention Type: Biological
Study Drug: Vedolizumab
Study Phase: Phase 4
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks
A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Other
Study Drug: Cx601
Study Phase: Phase 3
ENTYVIO® Real-World Outcomes in Bio-naïve Crohn's Disease Patients in Belgium, Australia, and Switzerland: An EVOLVE Observational Expansion Study
ENTYVIO® Real-World Outcomes in Bio-naïve Crohn's Disease Patients in Belgium, Australia, and Switzerland: An EVOLVE Observational Expansion Study
Enrollment Status: Completed
Publish Date: October 21, 2022
A Multicentre Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Tolerability, Efficacy, Dose-response, Pharmacokinetics and Pharmacodynamics of Repeat Dosing of an Anti-LAG3 Cell Depleting Monoclonal Antibody (GSK2831781) in Patients With Active Ulcerative Colitis
A Multicentre Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Tolerability, Efficacy, Dose-response, Pharmacokinetics and Pharmacodynamics of Repeat Dosing of an Anti-LAG3 Cell Depleting Monoclonal Antibody (GSK2831781) in Patients With Active Ulcerative Colitis
Enrollment Status: Terminated
Publish Date: April 27, 2022
Intervention Type: Drug
Study Drug: GSK2831781
Study Phase: Phase 2
Multicentric, Double-blind, Placebo Controlled Clinical Trial With 5-hydroxytryptophan (5-HTP) in Patients With Inflammatory Bowel Disease in Clinical and Biologic Remission: Effect on Fatigue Scores
Multicentric, Double-blind, Placebo Controlled Clinical Trial With 5-hydroxytryptophan (5-HTP) in Patients With Inflammatory Bowel Disease in Clinical and Biologic Remission: Effect on Fatigue Scores
Enrollment Status: Completed
Publish Date: May 18, 2021
Intervention Type: Drug
Study Drug: 5-HTP
Study Phase: Phase 2
View 8 Less Clinical Trials

336 Total Publications

Gaps between European Crohn's and Colitis Organisation quality standards of care and the real world on diagnosis and monitoring inflammatory bowel disease across Europe: results from the E-QUALITY survey.
Gaps between European Crohn's and Colitis Organisation quality standards of care and the real world on diagnosis and monitoring inflammatory bowel disease across Europe: results from the E-QUALITY survey.
Journal: Journal of Crohn's & colitis
Published: June 27, 2025
Similar Doctors
Expertise in
34
conditions
Dr. Mohammad A. Bilal
Radiology | Interventional Radiology
Expertise in
34
conditions
Dr. Mohammad A. Bilal
Radiology | Interventional Radiology

John T Mather Memorial Hospital

75 N Country Rd, 
Port Jefferson, NY 
 (25.1 miles away)
631-473-1320
Languages Spoken:
English
See accepted insurances

Mohammad Bilal is a Radiologist and an Interventional Radiologist in Port Jefferson, New York. Dr. Bilal is highly rated in 34 conditions, according to our data. His top areas of expertise are Gallbladder Disease, Ascites, Intussusception in Children, Endoscopy, and Colonoscopy.

Expertise in
25
conditions
Dr. Robert Lefkowitz
Radiology
Expertise in
25
conditions
Dr. Robert Lefkowitz
Radiology

Mskcc Radiology Group

650 Commack Rd, 
Commack, NY 
 (20.6 miles away)
631-623-4300
Languages Spoken:
English
See accepted insurances

Robert Lefkowitz is a Radiologist in Commack, New York. Dr. Lefkowitz is highly rated in 25 conditions, according to our data. His top areas of expertise are Fibrosarcoma, Liposarcoma, Alveolar Soft Part Sarcoma, Desmoid Tumor, and Prostatectomy.

Expertise in
1
conditions
Dr. Henry C. Kwok
Radiology
Expertise in
1
conditions
Dr. Henry C. Kwok
Radiology
1233 York Ave Apt 8j, 
New York, NY 
 (31.3 miles away)
917-455-2730
Languages Spoken:
English

Henry Kwok is a Radiologist in New York, New York. Dr. Kwok is highly rated in 1 condition, according to our data. His top area of expertise is Lump in the Abdomen.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ferrante's expertise for a condition
ConditionClose
    View All 47 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile